Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…h all patient biopsies, achieving the primary endpoint. Ex-vivo pembrolizumab response rate was 14% (2 of 14 samples evaluated thus far), whi…
…D, Griffith M, Griffith OL, Adkins DR. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated …
…g prostatic acid phosphatase (PAP, pTVG-HP) in combination with pembrolizumab in patients with metastatic, castration-resistant prostate canc…
…nter. Patients received either nivolumab + ipilimumab (n=21) or pembrolizumab monotherapy (n=31). Radiological responses were assessed using …
…ynx (25%), oral cavity (16.7%), hypopharynx (16.7%).Conclusions TU2218 in combination with Pembrolizumab in patients with HNSCC demons…
… patients with advanced non-small cell lung cancer who switched pembrolizumab from Q3W to Q6W between March 2017 and September 2023. Serum co…
…ment and on-treatment biopsies may inform treatment outcomes to pembrolizumab.Methods We evaluated 256 baseline and 248 on-treatment biopsies…
…or stromal expression were associated with response.Conclusions Talabostat plus pembrolizumab demonstrates preliminary anti-tumor activity…
…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…
…participation in the trial. Standard therapies considered were: pembrolizumab (adjuvant, high risk stage II–IV melanoma); dabrafenib + tramet…
…cinoma who received chemotherapy, whole breast radiotherapy and pembrolizumab (immune checkpoint inhibitor). During the sixth pembrolizumab c…
…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…